ArticleFrontiers in bioinformatics2026
CMA-DTI: a cross-modal fusion and attentive interaction network for interpretable drug-target interaction prediction.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-target interaction (DTI) prediction is an important task in early-stage drug discovery. Although deep learning methods have improved predictive performance, effectively integrating heterogeneous drug representations and providing interpretable evidence for local interaction patterns remain challenging. Methods: We propose CMA-DTI, a cross-modal fusion and attentive interaction framework for DTI prediction. CMA-DTI integrates GCN-based molecular graph representations, ChemBERTa-derived SMILES representations, and ESM-2 protein residue embeddings. An intra-drug cross-attention module models soft relevance patterns between graph nodes and SMILES tokens, while a drug-protein multi-head attention module captures local relevance between fused drug nodes and protein residues. Results: On BindingDB and BioSNAP, CMA-DTI achieved competitive performance compared with representative machine learning and deep learning baselines. Cold-drug and cold-target evaluations showed that the model retained predictive ability under unseen-drug and unseen-target settings. Ablation results indicated that intra-drug cross-attention performed better than concatenation, addition, and gated fusion. In a representative structural case, attention-ranked residues showed moderate enrichment in ligand-binding pocket residues compared with random rankings. Conclusion: CMA-DTI provides a practical framework for multimodal DTI prediction by combining graph structure, chemical language representations, and protein language model embeddings. Its attention patterns offer hypothesis-generating molecular relevance evidence, but should not be interpreted as causal mechanistic explanations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.